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ABSTRACT Invasive mold infections caused by molds other than Aspergillus spp.
or Mucorales are emerging. The reported prevalences of infection due to these
rare fungal pathogens vary among geographic regions, driven by differences in cli-
matic conditions, susceptible hosts, and diagnostic capabilities. These rare molds—
Fusarium, Lomentospora, and Scedosporium species and others—are difficult to detect
and often show intrinsic antifungal resistance. Now, international societies of medical
mycology and microbiology have joined forces and created the “Global guideline for
the diagnosis and management of rare mould infections: an initiative of the European
Confederation of Medical Mycology in cooperation with the International Society for
Human and Animal Mycology and the American Society for Microbiology” (published
in Lancet Infect Dis, https://doi.org/10.1016/S1473-3099(20)30784-2), with the goal of
improving the diagnosis, treatment, prevention, and survival of persons with rare
mold infections. The guideline provides cutting-edge guidance for the correct utili-
zation and application of established and new diagnostic and therapeutic options.
KEYWORDS Fusarium, Lomentospora, Paecilomyces, Penicillium, Phaeohyphomycosis,
Rasamsonia, Scedosporium, Scopulariopsis, basidiomycetes, diagnosis, molds, treatment
The fungal bloom at the end of the Cretaceous Period has favored the selection ofendothermic mammals over ectothermic reptiles, because the warm body temper-
atures of mammals protected them from fungal diseases (1). Since then, the world has
become a warmer place, and an increasing number of fungal species are adapting to
high temperatures and are emerging as important human pathogens (2). Due to
advances of modern medicine, new groups of patients at risk of developing invasive
fungal diseases (IFD), and particularly invasive mold disease, have been identified.
These patients include those with severe acute respiratory syndrome coronavirus 2 or
influenza virus A or B, requiring intensive care (3, 4), and those receiving biological
therapies (such as tumor necrosis factor alpha inhibitors) and new small-molecule ki-
nase inhibitors (such as ibrutinib and idelalisib) (5). Mold-active antifungal prophylaxis
in those at highest risk for invasive aspergillosis has proven effective in preventing
invasive aspergillosis and, to a lesser extent, also mucormycosis (6, 7). However, the
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selective pressure of antifungal prophylaxis may also contribute to the emergence of less
common invasive mold infections, caused by molds that are often intrinsically resistant to
some classes of antifungals, including Fusarium, Lomentospora, and Scedosporium species,
as well as even less common emerging molds, such as Rasamsonia, Schizophyllum,
Scopulariopsis, Purpureocillium, and Paecilomyces spp., which have been described as
opportunistic pathogens in patients with a variety of underlying diseases (8–10). The
intrinsic resistance of the fungal pathogens to many of the available antifungals limits
successful therapeutic options (11, 12). The reported prevalences of infection due to
these rare fungal pathogens vary widely among geographic regions, driven by differen-
ces in climatic conditions, susceptible hosts, and diagnostic capabilities (10–14). The
increasing availability of new nucleic acid amplification assays, blood culture detection
systems, and lateral flow devices, as well as matrix-assisted laser desorption ionization–
time of flight (MALDI-TOF) mass spectrometry for the detection of medically important
fungi and the laboratory diagnosis of invasive mycoses, warrants guidance in their use in
clinical practice. Also, therapeutic options differ across global regions, and guidance
needs to reflect this to optimize patient management.
Now, international societies of medical mycology and microbiology have joined
forces with the goal of improving the diagnosis, treatment, prevention, and survival of
persons with rare mold infections. For the in-press “Global Guideline for the Diagnosis
and Management of Rare Mold Infections: an Initiative of the European Confederation
of Medical Mycology (ECMM) in Cooperation with the International Society for Human
and Animal Mycology (ISHAM) and the American Society for Microbiology (ASM)” (15),
medical professionals from around the world, representing all United Nations regions
and all medical disciplines involved in the management of invasive mold diseases, con-
tributed their expertise and analyzed published evidence to develop global guidance
for the diagnosis and management of rare mold infections. During the 6-week public
review phase, over 350 comments and suggestions were submitted and subsequently
incorporated into the guideline. Specifically, the 3 reviewers appointed by the ASM
provided outstanding detailed reviews, which further improved the diagnostic, labora-
tory, and treatment aspects of the guideline significantly. The guideline takes into
account that available diagnostic and therapeutic options differ across global regions
and gives out recommendations stratified for high- and low-resource countries.
Evidence-based diagnostic strategies and approaches, both primary and ancillary in na-
ture, are clearly delineated in this document. Advantages and disadvantages of various
diagnostic methods are outlined and will prove helpful for laboratorians and clinicians
alike. The inclusion of excellent photomicrographs of microscopic morphologies
obtained from colonial growth, as well as typical histopathologic appearances in tissue,
provides a wealth of information on these rare pathogens for anatomic pathologists
and medical microbiologists. The present recommendations comprise the second
guidance document of the One World-One Guideline initiative (after the mucormycosis
guideline, which was published in 2019) (16, 17) to incorporate regional differences in
epidemiology and management, and the guidance document was reviewed and
endorsed by 54 scientific societies, including national societies from 38 countries and
several international societies.
While previous guidelines in this area (i) were limited to individual rare mold patho-
gens (18–20) and focused on specific groups of patients, such as those with hematologi-
cal malignancies (20), or (ii) were missing altogether for infections caused by many of
the very rare, but emerging, pathogenic molds, this new comprehensive guideline over-
comes these problems by leveraging online resources, including shared folders, video-
and teleconferences, YouTube tutorials (e.g., https://www.ecmm.info/guidelines/), and
training materials, which have become essential because of the fact that face-to-face
meetings in the context of worldwide contributions are not feasible (which was true
even before the coronavirus disease 2019 pandemic) and to ensure short timelines to
guideline completion. In fact, the short timeline to completion is a strength of the cur-
rent guideline on rare molds, which includes evidence that came out during recent
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months of 2020, such as the superiority of lomentosporiosis treatment with voriconazole
and terbinafine combination versus monotherapy (11).
Utilization of new online tools to facilitate worldwide exchange and knowledge
sharing, including educational videos, are now indispensable in our increasingly global
world. By using these online resources, ambitious goals like worldwide guidelines sud-
denly become feasible, as communication and decision-making are transparent, quick,
and not restricted to planned, comparatively expensive in-person meetings, where a
major challenge is to bring together experts from all regions around the globe to dis-
cuss matters.
In conclusion, in the context of a growing population of immunocompromised
patients at risk of opportunistic infections, the prevalence of invasive fungal disease
caused by emerging and often drug-resistant rare molds is on the rise. While new
diagnostic and therapeutic options are now available to tackle IFD, cutting-edge
guidance for their correct utilization and application in a range of clinical settings is
provided within this guideline document, focusing on infections caused by Fusarium
spp., Lomentospora spp., Scedosporium spp., dematiaceous molds causing phaeohy-
phomycosis, Rasamsonia spp., Scopulariopsis spp., Penicillium spp., non-marneffei
Talaromyces spp., Paecilomyces spp., Purpureocillium spp., and Schizophyllum spp., as
well as other basidiomycetes.
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